专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09352016B2 Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces 有权
标题翻译：用于用医学程序给药的因子XII抑制剂，包括与人造表面接触
公开(公告)号：US09352016B2
公开(公告)日：2016-05-31
申请号：US14004066
申请日：2012-03-09
申请人： Stefan Zeitler , Marc Nolte , Stefan Schulte , Gerhard Dickneite , Ingo Pragst
发明人： Stefan Zeitler , Marc Nolte , Stefan Schulte , Gerhard Dickneite , Ingo Pragst
IPC分类号： A61K9/00 , A61K36/00 , A61K38/16 , A61K38/55 , A61K38/57 , C07K16/36 , C07K16/40 , A61K31/727 , A61K38/17 , A61K47/48
CPC分类号： A61K38/1767 , A61K31/727 , A61K38/16 , A61K38/556 , A61K38/57 , A61K38/58 , A61K39/3955 , A61K47/643 , A61K47/65 , A61L33/0041 , A61L33/0082 , A61L33/128 , A61L2300/252 , A61L2300/256 , A61L2300/42 , A61L2420/00 , C07K16/36 , C07K16/40 , C07K2317/76
摘要： An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
摘要翻译： FXII / FXIIa的抑制剂，用于在对人或动物受试者进行的医疗过程期间和/或之后防止血栓的形成和/或稳定化，包括使人或动物受试者的血液与人造表面接触，其中所述抑制剂 FXII / FXIIa在所述医疗程序之前和/或期间和/或之后施用。

2. 发明授权

US08508749B2 Method of measuring a deviation of an optical surface from a target shape using interferometric measurement results 有权
标题翻译：使用干涉测量结果测量光学表面与目标形状的偏差的方法
公开(公告)号：US08508749B2
公开(公告)日：2013-08-13
申请号：US13609084
申请日：2012-09-10
申请人： Ralf Arnold , Stefan Schulte , Bernd Doerband
发明人： Ralf Arnold , Stefan Schulte , Bernd Doerband
IPC分类号： G01B11/02
CPC分类号： G01B9/021 , G01B9/02039 , G01B11/2441 , G01M11/025 , G01M11/0271 , Y10T29/49771
摘要： A method of measuring a deviation of an optical surface from a target shape and a method of manufacturing an optical element. This method of measuring the deviation includes: performing a first interferometric measurement using a first diffractive measurement structure, which is arranged to cover a first area of the optical surface, to provide a first interferometric measurement result, performing a second interferometric measurement using a second diffractive measurement structure, which is arranged to cover a second area of the optical surface different from the first area, to provide a second interferometric measurement result, and determining a deviation of the optical surface from the target shape.
摘要翻译：测量光学表面与目标形状的偏差的方法和制造光学元件的方法。这种测量偏差的方法包括：使用被布置成覆盖光学表面的第一区域的第一衍射测量结构来执行第一干涉测量，以提供第一干涉测量结果，使用第二衍射进行第二干涉测量测量结构被布置成覆盖与第一区域不同的光学表面的第二区域，以提供第二干涉测量结果，以及确定光学表面与目标形状的偏差。

3. 发明申请

US20100177320A1 METHOD OF MEASURING A DEVIATION OF AN OPTICAL SURFACE FROM A TARGET SHAPE 有权
标题翻译：测量目标形状的光学表面偏差的方法
公开(公告)号：US20100177320A1
公开(公告)日：2010-07-15
申请号：US12684600
申请日：2010-01-08
申请人： Ralf Arnold , Stefan Schulte , Bernd Doerband
发明人： Ralf Arnold , Stefan Schulte , Bernd Doerband
IPC分类号： G01B11/02 , G02B13/18
CPC分类号： G01B9/021 , G01B9/02039 , G01B11/2441 , G01M11/025 , G01M11/0271 , Y10T29/49771
摘要： A method of aligning at least two wave shaping elements, a method of measuring a deviation of an optical surface from a target shape and a measuring apparatus for interferometrically measuring a deviation of an optical surface from a target shape. The method of aligning at least two wave shaping elements, each of which wave shaping elements has a diffractive measurement structure for adapting part of a wave front of incoming light to a respective portion of the target shape, includes: providing a first one of the wave shaping elements with a diffractive alignment structure, arranging the wave shaping elements relative to each other such that each of the diffractive measurement structures is traversed by a separate subset of rays of the incoming light during operation of the measuring apparatus, and aligning the first wave shaping element and a second one of the wave shaping elements relative to each other by evaluating alignment light having consecutively interacted with the diffractive alignment structure and with the second wave shaping element.
摘要翻译：对准至少两个波形整形元件的方法，测量光学表面与目标形状的偏差的方法和用于干涉测量光学表面与目标形状的偏差的测量装置。对准至少两个波形整形元件的方法，其中每个波形整形元件具有衍射测量结构，用于将入射光的一部分波前适应到目标形状的相应部分，包括：提供第一波具有衍射对准结构的成形元件，将波形整形元件相对于彼此布置，使得每个衍射测量结构在测量设备的操作期间被入射光的单独的子集子穿过，并且对准第一波形整形元件和第二波形成形元件相对于彼此，通过评估与衍射对准结构和第二波形整形元件连续相互作用的对准光。

4. 发明申请

US20100120664A1 MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE 有权
标题翻译：改良的凝血因子与生殖健康生活息息相关
公开(公告)号：US20100120664A1
公开(公告)日：2010-05-13
申请号：US12520840
申请日：2007-12-21
申请人： Stefan Schulte , Thomas Weimer , Hubert Metzner
发明人： Stefan Schulte , Thomas Weimer , Hubert Metzner
IPC分类号： A61K38/16 , C07K14/745 , C07K14/755 , C07H21/00 , C12N15/74 , C12N5/10 , C12P21/00 , A61P7/04
CPC分类号： C07K14/755 , C07K14/745 , C07K14/765 , C07K16/18 , C07K2319/31
摘要： The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.
摘要翻译：本发明涉及编码改性凝血因子，优选凝血因子VIII及其衍生物的核酸序列; 含有该核酸序列的重组表达载体; 用这些重组表达载体转化的宿主细胞; 和由所述核酸序列编码的重组多肽和衍生物，其中与未修饰的野生型蛋白相比，所述重组多肽和衍生物具有生物学活性和延长的体内半衰期。本发明还涉及导致体外稳定性改善的相应序列。本发明还涉及制备这些重组蛋白及其衍生物的方法。本发明还涉及用于人基因治疗的转移载体，其包含这样的核酸序列。

5. 发明授权

US07550567B2 Fibrinogen purification 有权
标题翻译：纤维蛋白原净化
公开(公告)号：US07550567B2
公开(公告)日：2009-06-23
申请号：US11062432
申请日：2005-02-23
申请人： Hubert Metzner , Uwe Liebing , Annette Feussner , Joerg Lemmer , Stefan Schulte , Volker Gawantka
发明人： Hubert Metzner , Uwe Liebing , Annette Feussner , Joerg Lemmer , Stefan Schulte , Volker Gawantka
IPC分类号： C07K14/75 , C07K1/16
CPC分类号： C07K14/75
摘要： The present invention relates to a process for purifying fibrinogen, which comprises one or more process steps in which one or more contaminating proteins are depleted by negative chromatography and/or negative adsorption using cation exchanger, hydrophobic gel and/or dye gel. In addition, the invention relates to the fibrinogen which is obtained by the process of the invention and which is notable for improved stability, and to the production and use of pharmaceutical preparations comprising this fibrinogen.
摘要翻译：本发明涉及一种用于纯化纤维蛋白原的方法，其包括一个或多个工艺步骤，其中一种或多种污染蛋白质通过阴离子色谱法和/或使用阳离子交换剂，疏水性凝胶和/或染料凝胶的负吸附来消耗。此外，本发明涉及通过本发明的方法获得并且其显着改进的稳定性的纤维蛋白原以及包含该纤维蛋白原的药物制剂的生产和使用。

6. 发明申请

US20080260755A1 Proteolytically cleavable fusion proteins with high molar specific activity 有权
标题翻译：具有高摩尔比活性的蛋白水解切割融合蛋白
公开(公告)号：US20080260755A1
公开(公告)日：2008-10-23
申请号：US12000739
申请日：2007-12-17
申请人： Hubert Metzner , Thomas Weimer , Stefan Schulte
发明人： Hubert Metzner , Thomas Weimer , Stefan Schulte
IPC分类号： A61K39/395 , C07K16/18 , C07K14/00 , C12N15/11 , A61K31/70 , A61P7/00 , A61K38/00 , C12N15/00 , C12N5/06 , C12P21/04
CPC分类号： C12N9/6437 , A61K38/00 , A61K48/00 , C07K14/745 , C07K14/755 , C07K14/76 , C07K14/765 , C07K2319/31 , C07K2319/50 , C12N9/6424 , C12N9/6443 , C12N9/6472 , C12Y304/21021 , C12Y304/21022
摘要： The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.
摘要翻译：本发明涉及治疗融合蛋白，其中凝血因子与半衰期增强多肽融合，并且其中两者通过可蛋白水解切割的接头肽连接。这种接头的切割将凝血因子从半衰期增强多肽引起的活性损害的空间位阻释放，从而允许融合蛋白的产生在凝血相关测定中测试时可显示相对高的摩尔比活性。此外，与通过具有氨基酸序列GGGGGGV的不可切割接头连接的相应治疗性融合蛋白测量的速率相比，接头可切割的事实可增加肽接头的蛋白水解切割后的失活和/或消除速率。

7. 发明授权

US07123365B1 Method of calibrating an interferometer optics and method of processing an optical element having an aspherical surface 失效
标题翻译：校准干涉仪光学元件的方法和处理具有非球面表面的光学元件的方法
公开(公告)号：US07123365B1
公开(公告)日：2006-10-17
申请号：US10792755
申请日：2004-03-05
申请人： Stefan Schulte
发明人： Stefan Schulte
IPC分类号： G01B9/02
CPC分类号： G01M11/0271 , G01B9/02038 , G01B9/02057 , G01B9/02072 , G01M11/025
摘要： A method of processing an optical element comprises providing an interferometer optics; arranging a calibrating substrate in a beam of measuring light emitted by the interferometer optics; superimposing measuring light having traversed the first and second surfaces of the calibrating substrate with reference light, and taking a first interferometric measurement of the superimposed measuring light and reference light; arranging the aspherical surface of the optical element in the beam of measuring light emitted by the interferometer optics, while the calibrating substrate is not arranged in the beam of measuring light; superimposing measuring light having interacted with the aspherical surface and the reference light, and taking a second interferometric measurement of the superimposed measuring light and reference light; determining deviations of the aspherical surface from a target shape thereof in dependence of the first and second measurements; and machining the aspherical surface of the optical element.
摘要翻译：一种处理光学元件的方法包括提供干涉仪光学元件; 将校准基板布置在由所述干涉仪光学器件发射的测量光束中; 叠加用参考光穿过校准基板的第一表面和第二表面的测量光，并对叠加的测量光和参考光进行第一干涉测量; 将光学元件的非球面布置在由干涉仪光学器件发射的测量光束中，同时校准基板未布置在测量光束中; 叠加与非球面和参考光相互作用的测量光，并对叠加的测量光和参考光进行第二干涉测量; 根据第一和第二测量确定非球面与其目标形状的偏差; 并加工光学元件的非球面。

8. 发明申请

US20050197493A1 Fibrinogen purification 有权
标题翻译：纤维蛋白原净化
公开(公告)号：US20050197493A1
公开(公告)日：2005-09-08
申请号：US11062432
申请日：2005-02-23
申请人： Hubert Metzner , Uwe Liebing , Annette Feussner , Joerg Lemmer , Stefan Schulte , Volker Gawantka
发明人： Hubert Metzner , Uwe Liebing , Annette Feussner , Joerg Lemmer , Stefan Schulte , Volker Gawantka
IPC分类号： A61K38/00 , A61P7/04 , C07K1/16 , C07K1/30 , C07K1/34 , C07K14/75
CPC分类号： C07K14/75
摘要： The present invention relates to a process for purifying fibrinogen, which comprises one or more process steps in which one or more contaminating proteins are depleted by negative chromatography and/or negative adsorption using cation exchanger, hydrophobic gel and/or dye gel. In addition, the invention relates to the fibrinogen which is obtained by the process of the invention and which is notable for improved stability, and to the production and use of pharmaceutical preparations comprising this fibrinogen.
摘要翻译：本发明涉及一种用于纯化纤维蛋白原的方法，其包括一个或多个工艺步骤，其中一种或多种污染蛋白质通过阴离子色谱法和/或使用阳离子交换剂，疏水性凝胶和/或染料凝胶的负吸附来消耗。此外，本发明涉及通过本发明的方法获得并且其显着改进的稳定性的纤维蛋白原以及包含该纤维蛋白原的药物制剂的生产和使用。

9. 发明授权

US09290561B2 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life 有权
标题翻译：因子VIII，血管性血友病因子或其复合物具有延长的体内半衰期
公开(公告)号：US09290561B2
公开(公告)日：2016-03-22
申请号：US14028869
申请日：2013-09-17
申请人： Thomas Weimer , Stefan Schulte , Hubert Metzner , Ulrich Kronthaler , Holger Lind , Wiegand Lang
发明人： Thomas Weimer , Stefan Schulte , Hubert Metzner , Ulrich Kronthaler , Holger Lind , Wiegand Lang
IPC分类号： A61K38/37 , A61K38/36 , A61K38/38 , A61K38/16 , A61K35/14 , C07K1/00 , C07K14/76 , C07K14/755 , A61K38/00
CPC分类号： C07K14/76 , A61K38/00 , C07K14/755 , C07K2319/31
摘要： The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.
摘要翻译：本发明涉及编码凝血因子VIII（FVIII）和von Willebrand因子（VWF）的修饰的核酸序列及其复合物及其衍生物，含有此类核酸序列的重组表达载体，用这种重组表达转化的宿主细胞载体，重组多肽和由所述核酸序列编码的衍生物，所述重组多肽和衍生物与未修饰的野生型蛋白质相比具有生物活性以及延长的体内半衰期和/或改善的体内恢复。本发明还涉及导致表达产量提高的相应FVIII序列。本发明还涉及制备这些重组蛋白及其衍生物的方法。本发明还涉及用于人基因治疗的转移载体，其包含这种修饰的核酸序列。

10. 发明授权

US08765915B2 Modified coagulation factor VIIa with extended half-life 有权
标题翻译：改性凝血因子Ⅶa具有延长的半衰期
公开(公告)号：US08765915B2
公开(公告)日：2014-07-01
申请号：US12223616
申请日：2007-02-03
申请人： Thomas Weimer , Stefan Schulte , Ulrich Kronthaler , Wiegand Lang , Uwe Liebing , Wilfried Wormsbächer
发明人： Thomas Weimer , Stefan Schulte , Ulrich Kronthaler , Wiegand Lang , Uwe Liebing , Wilfried Wormsbächer
IPC分类号： A61K38/35 , A61K38/38 , C07K14/745 , C07K14/76 , C07K14/765 , C12N9/64 , A61K38/00
CPC分类号： A61K38/4846 , A61K9/0019 , A61K38/00 , A61K38/385 , C07K14/76 , C07K2319/00 , C07K2319/31 , C12N9/6437 , C12N9/96 , C12N15/62 , C12Y304/21021
摘要： The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
摘要翻译：本发明涉及因子VII（FVII）和因子VIIa（FVIIa）白蛋白连接多肽的领域。更具体地，本发明涉及编码人因子VII和因子VIIa的cDNA序列和与编码人血清白蛋白的cDNA遗传融合的衍生物，其可以通过寡核苷酸连接，所述寡核苷酸编码干扰肽接头，这种编码的衍生物表现出改进的稳定性和延长的功能血浆半衰期，含有这些cDNA序列的重组表达载体，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白的生物活性但具有改善的稳定性和延长的保存期限的重组多肽和衍生物制备这些重组蛋白及其衍生物。本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式